Fireside Chat with Sir An0drew Witty | Part 2 Fast Forward: A Glimpse Into Asia-Pacific's Future

GSK Leadership and Global Health Strategy

• Singapore as Global Hub: GSK is establishing its third global headquarters in Singapore (opening March next year) to manage operations for the time zone up to Istanbul, aiming to decentralize decision-making from London to the region.
• Manufacturing Scale: Singapore hosts three major GSK factories and a state-of-the-art vaccine facility; the region supplies approximately 50% of the world's active pharmaceutical ingredients.
• Life Expectancy Drivers: Sir Andrew Witty attributes the doubling of average global life expectancy from 40 years (1916) to over 80 years (2024) primarily to clean water, vaccines, pharmaceuticals, and increased calorie intake, with the pharmaceutical industry responsible for two of these four factors.
• Access and Pricing Strategy: GSK has implemented tiered pricing and waived intellectual property rights for the 60 poorest countries, arguing that "innovation that nobody can access is not an innovation."
• Africa Investment: GSK donates 20% of profits made in sub-Saharan Africa (the 60 poorest countries) to local healthcare infrastructure, resulting in the training of 40,000 frontline workers covering 11 million people by 2020, with a target of 150,000 workers covering 150 million people.
• HIV Treatment Milestones: GSK and partners exceeded the Millennium Goal for HIV treatment, reaching 17 million people treated (target was 15 million), and reduced mother-to-child transmission rates from 90% to 2% with proper treatment.
• Drug Discovery Challenges: Witty cited the development of Lamivudine (3TC) as a case study of uncertainty; the drug initially showed resistance issues, but a combination with AZT unexpectedly disabled the virus, breaking the back of HIV management.
• CEO Succession and Requirements: Witty is stepping down next year, emphasizing that future CEOs must possess the courage to fundamentally change business models (including R&D and customer engagement) rather than just executing existing strategies.
• Industry Reputation: GSK has committed to publishing all clinical trial results (successful or not), changing sales force compensation structures to avoid conflicts of interest, and ending payments to doctors for speaking on their behalf.

Asia-Pacific Economic Outlook and Investment Trends

• Growth Stagnation Concerns: Panelists acknowledge global growth risks, with a McKinsey report suggesting global growth could halve; the Asia-Pacific region faces potential prolonged low growth, particularly if China's economic slowdown worsens.
• China Economic Pivot: China is transitioning from an export/infrastructure-led model to one driven by domestic consumption, though this transition carries risks of a prolonged "Japan-style" stagnation if not managed successfully.
• Demographic Advantages: Southeast Asia (specifically Indonesia, Philippines, and India) possesses structural growth drivers including population growth, urbanization, rising middle classes, and high savings rates, which are viewed as more resilient than cyclical factors.
• Investment Strategy Shifts: Investors are moving away from broad "beta" bets and large buyouts toward onshore private equity, growth equity, and early-stage technology sectors to mitigate risks from slowing macroeconomic growth.
• Japan's Savings Paradox: Japan holds over 900 trillion yen in savings (more than half the country's financial assets), but negative interest rates have failed to stimulate spending, leading to increased hoarding and a difficult environment for unlocking individual capital.
• Fourth Industrial Revolution Risks: Technological advancements (AI, robotics, 3D printing) pose significant risks of job disintermediation, particularly in manufacturing, though they may simultaneously create new markets and service-based employment opportunities.
• Geopolitical Risks: Panelists identified interest rate hikes in the US (strengthening the dollar) and political governance instability as major risks, with Brexit serving as a "red flag" for global populism and wealth disparity in developed economies.
• Regulatory Barriers: A primary constraint on Asian capital growth remains inconsistent regulatory environments, including issues with rule of law, transparency, and capital convertibility, which hinder foreign direct investment.
• Sector Opportunities: Key growth sectors identified include healthcare (genomics, immunology), education, infrastructure development (specifically in India and Indonesia), and technology-driven services (O2O models in China).
• Panel Optimism: Despite headwinds, the consensus among investors (Future Fund, GIC, GPIF, AIA) leans toward optimism for the long term, with specific preference for markets that can execute internal growth pivots despite short-term volatility.